XILIO THERAPEUTICS INC (XLO:NASDAQ)
$8.52 0.18 (2.1583%)
Analysed XILIO THERAPEUTICS INC (XLO:NASDAQ) News Sources
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
23-03-2026
yahoo.com
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
26-03-2026
yahoo.com
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
01-04-2026
yahoo.com
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
16-04-2026
yahoo.com
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
17-04-2026
yahoo.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07-05-2026
yahoo.com
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
11-05-2026
yahoo.com
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
12-05-2026
yahoo.com
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
12-05-2026
yahoo.com
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
12-05-2026
yahoo.com
What is the current price of XILIO THERAPEUTICS INC (XLO:NASDAQ)?
The current price of XILIO THERAPEUTICS INC (XLO:NASDAQ) is $8.52.
XILIO THERAPEUTICS INC (XLO:NASDAQ) absolute price change since previous trading day?
The absolute price change of XILIO THERAPEUTICS INC (XLO:NASDAQ) since the previous trading day is $0.18.
XILIO THERAPEUTICS INC (XLO:NASDAQ) percentage price change since previous trading day?
The percentage price change of XILIO THERAPEUTICS INC (XLO:NASDAQ) since the previous trading day is 2.1583%.
What is the most recent average sentiment score for XILIO THERAPEUTICS INC (XLO:NASDAQ)?
The most recent average sentiment score for XILIO THERAPEUTICS INC (XLO:NASDAQ) is 60 out of 100.
What is the most recent average sentiment for XILIO THERAPEUTICS INC (XLO:NASDAQ)?
The most recent sentiment for XILIO THERAPEUTICS INC (XLO:NASDAQ) is .
SEC-8K** Filing Available For XILIO THERAPEUTICS INC (XLO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.